UnknownNot Applicable

Arrhythmogenic Substrate in Primary Cardiomyopathies and/or Channellopathies

Italy35 participantsStarted 2018-01-24

Plain-language summary

This study assesses the value of arrhythmogenic substrate identification and elimination by catheter ablation to prevent recurrent ventricular arrhythmias and sudden cardiac death in a series of selected patients with primary cardiomyopathy and/or channellopaties with ICD implantation.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients affected by cardiomyopathies and/or channellopaties (long QT syndrome and J-wave syndrome) with and without documented family history of BrS; * Presence of symptoms attributable to VA and/or presenting documented arrhythmic episodes; * Patients with an ICD already implanted; * Patients referred to the centre for an electrophysiological study and indication for a potential concomitant radio-frequency catheter ablation (RFA) of ventricular tachycardia (VT) or ventricular fibrillation (VF); * Age ≥ 18; * Willingness to attend follow-up examinations; * Written informed consent for the participation in the trial Exclusion Criteria: * Pregnancy or breast-feeding; * Life expectancy \< 12 months

What they're measuring

Freedom from ventricular fibrillation or ventricular tachycardia

Timeframe: two years

Trial details

NCT IDNCT03304847

SponsorIRCCS Policlinico S. Donato

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-10-02

Contact for this trial

Carlo Pappone, MD

+39 02 52774260 carlo.pappone@af-ablation.org

View on ClinicalTrials.gov More Cardiomyopathy trials